A 61-year-old man with a failing heart chose to have his own removed and replaced with a device made of polyurethane and aluminum. On December 2, 1982, at the University of Utah Medical Center, a surgical team led by William DeVries implanted the Jarvik-7 into Barney Clark. The procedure lasted seven and a half hours. Clark survived the operation. He lived for 112 more days, tethered by six-foot air hoses to a 375-pound console that hissed and clicked as it powered the artificial organ.
This event matters not as a clinical success—Clark suffered from strokes, seizures, and confusion—but as an existential threshold. It forced a new question: what constitutes life when sustained by machine? Clark was never again a free-moving person. His existence was a series of medical crises managed in a hospital room. The experiment was as much philosophical as surgical.
The common narrative frames this as a brave step toward modern mechanical hearts. A more precise view sees it as a necessary, grim failure that defined the limits of replacement. The Jarvik-7 was not a cure; it was a bridge with no destination. The device kept Clark's body alive while his condition deteriorated in other ways. His ordeal informed bioethical debates on quality of life and informed consent for experimental procedures.
The lasting impact was a pivot in strategy. The failure of permanent total artificial hearts led the field to focus on temporary ventricular assist devices as bridges to transplant, and later, on smaller, implantable partial assist systems. Clark's experience drew a clear line: a machine could assume the function of an organ, but the human cost of a crude substitution was unacceptably high. The goal shifted from replacing the heart to assisting it.